TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Bioequivalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 Trough Value (Assay Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 Trough Value (Bioequivalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of 123I-mIBG scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by AFEQT Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: driving evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control of steering wheel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control of speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrauterine Growth Restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from Baseline Child Cognitive Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Behaviour Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of health care practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite clinical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change of blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total absence of sensitivity and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by visual analogue pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle Sympathetic Nerve Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in headache days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Immune system development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diet adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of intravitreal injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Device Response Assessed by Asynchronous Pacing When Using a Smart Phone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Asynchronous Pacing While Using a Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Inhibition of Ventricular Pacing While Using a Smart Phone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of patients with end stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Administered dose of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Failure or Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance of quadriceps thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) Based on Local Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching diastolic BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients reaching systolic BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gestational Trophoblastic Neoplasia features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IL-6 protein production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of depression and/or anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse and/or survival times
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of herpes virus infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Cure at End of Study
Endpoint domain: Mortality/survival
Primary endpoint: Days alive without life support at day 28
Endpoint domain: Mortality/survival
Primary endpoint: skin lesion condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neurologic outcomes after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: extinction retention index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional neuroimaging measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNFLT/TRT Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Global Aesthetic Improvement Scale (GAI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of left ventricular thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathologic Complete Response (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events after CD4 CAR T cells cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in supine blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Increase in Tumor and Stroma With Infiltrating Lymphocytes (TIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Carotid Femoral Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: disease exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: hospitalizations of patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: patients requiring surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of diversity of intestinal flora in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of diversity of urethral flora in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of diversity of oral flora in pharyngeal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of diversity of flora in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of abundance of intestinal flora in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change from baseline in bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline in crestal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Information needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Grief Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: endotoxin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Modified-Incremental Shuttle Walk Test (ISWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation to Klinefelter syndrome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provider Treatment Fidelity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of joint kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in IKDC subjective
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of patients with alteration of the capillary alveolus barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients Waitlisting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wait Listing Disparity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantity of nitrate-reducing bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy (clinical benefit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locoregional control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patterns of failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of silent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device-related HAI rates
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Heat Pain Threshold (HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Cold Pain Threshold (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Tolerance to Heat Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Were Seropositive for Anti-Drug Antibodies (ADAs) After CCH-aaes Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Component Positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brain oxygen tension level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cleaved tau protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Cognitive-Behavioral Therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BMD percentage change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transplant graft outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney graft outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: sitting diastolic blood pressure (sitDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate of gastric low-grade MALT lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Transition rate to secondary therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: TREM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean maximum symptom days per 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Area under the plasma drug concentration curve (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration time curve (AUC0-tf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood cell biomarker level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants completing recommended screenings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: KOOS/HOOS-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptable symptom state (PASS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-emergent adverse events (TEAE) - SAD
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent adverse events (TEAE) - MAD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of detected venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: SALT Score (Severity of Alopecia Tool)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in meters walked during the six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment decision adequacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engraftment after CD3/CD19 depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting and postprandial blood glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting and postprandial insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satiety-producing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary efficacy of the intervention in changing pain-related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary efficacy of the intervention in changing pain-related outcomes as measured by medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of neutrophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity of the mobilization procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Adherence to Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Participant Safety With the Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Time to need for symptomatic treatment with dopaminergic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IFN-γ ELISPOT response to HIV-1 peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in managerial practices
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Sensitivity against microbiological reference standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity against microbiological reference standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications related to arteriovenous fistula puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve of Carbamazepine in plasma (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of Carbamazepine in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentration of Carbamazepine in plasma at 12 hours (Cp12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Occurrence of Any Acute Otitis Media (AOM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in filtration fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dyschesia evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of NRL972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death and mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Locoregional or disseminated infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: operation theatre time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of syncope or presyncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Altered disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline In Serum LDH Levels At Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with severe skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of shoulder dystocia
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of pH-MII GERs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Experimental mechanism based Pain Measures (EPMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attributable Length of Stay (ALOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospital COSTS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knee articular cartilage Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee articular cartilage Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee articular cartilage Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee pain evaluation (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee pain evaluation (Lysholm Knee Scoring Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: White Matter Hyperintensity Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Implanted Patients With Improvement of at Least 50% in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain Score Over the Last 8 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal status of adjacent second molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Calcium kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve from time of dosing to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Apnea Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest wall fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Fugl-Meyer Lower Extremity (FMLE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in coronary microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of most abundant serum protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of second most abundant serum protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of stool biomarker interleukin-8 (IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of stool biomarker calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of the DLTEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Positive Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Antibody Concentrations (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Antibody Concentration (Titer) at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes